Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-Susceptible Staphylococcus pseudintermedius to Empirical Co-Trimoxazole for Canine Pyoderma

The prevalence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) that causes pyoderma has been gradually shifting, according to many surveillance studies, with annual changes. The empirical co-trimoxazole regimen remains interesting, but research on co-trimoxazole susceptibility to MRS...

Full description

Saved in:
Bibliographic Details
Published inLife (Basel, Switzerland) Vol. 13; no. 5; p. 1210
Main Authors Khongsri, Usasom, Chongrattanameteekul, Peerawit, Chantarachart, Sineenart, Photichai, Kornravee, Chanayat, Nittaya, Varinrak, Thanya, Mektrirat, Raktham, Srifawattana, Nuttawan
Format Journal Article
LanguageEnglish
Published MDPI AG 18.05.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The prevalence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) that causes pyoderma has been gradually shifting, according to many surveillance studies, with annual changes. The empirical co-trimoxazole regimen remains interesting, but research on co-trimoxazole susceptibility to MRSP is limited. The objective of this study was to evaluate the susceptibility of co-trimoxazole to canine pyoderma MRSP isolates. Sixty isolates of S. pseudintermedius were identified as 16 MRSP and 44 methicillin-susceptible S. pseudintermedius (MSSP) using an oxacillin disk diffusion test and VITEK 2 system with VITEK GP card. Using the VITEK 2 system with a VITEK AST-GP81 card, the susceptibility rates of MRSP (15.00%) and MSSP (35.00%) to co-trimoxazole was observed. The median MIC of co-trimoxazole on MSSP (median, ≤10; IQR, 10–320) was lower than that of MRSP (median, ≥320; IQR, 10–320) (p = 0.5889, Mann-Whitney test). Percent attainment of PK/PD targets in MRSP (q 12 h, 43.75; q 8 h, 43.75) were lower than that of MSSP (q 12 h, 52.27; q 8 h, 52.27) (p = 0.7710). These findings show the moderately phenotypic co-trimoxazole susceptibilities of both MRSP and MSSP. Further study is required to develop clinical trials examining the use of co-trimoxazole in dogs with pyoderma.
ISSN:2075-1729
2075-1729
DOI:10.3390/life13051210